Why is Mankind Pharma falling/rising?

As of 10-Jul, Mankind Pharma Ltd's stock price is currently at 2,543.40, reflecting an increase of 18.1 points or 0.72%. The stock has shown strong performance recently, gaining 5.02% over the last three days and outperforming its sector by 1.29% today. It is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating positive momentum. Additionally, the stock has generated an impressive return of 18.19% over the past year, significantly outpacing the broader market's return of 1.46%. Factors contributing to this rise include high management efficiency, as evidenced by a return on equity (ROE) of 19.25%, and a low debt-to-equity ratio, which suggests financial stability. However, there are concerns regarding the company's recent negative results, particularly a significant drop in profit before tax and a high price-to-book value ratio, indicating that the stock may be overvalued compared to its peers.
Broader Market Context: In the short term, Mankind Pharma's stock has outperformed the benchmark Sensex, which has seen a slight decline of 0.06% over the past week while Mankind Pharma has risen by 7.59%. This contrast highlights the stock's relative strength in a challenging market environment. Despite the broader market's mixed performance, Mankind Pharma's strong institutional holdings at 24.4% and rising investor participation, as indicated by a 157.1% increase in delivery volume, suggest that investors are confident in the company's long-term growth potential, despite some recent negative financial indicators.